Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants with Advanced Solid Tumors
Conditions
Interventions
SNV1521
Trastuzumab Deruxtecan
Locations
9
United States
Yale University
New Haven, Connecticut, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
The University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States
START Center for Cancer Care
West Valley City, Utah, United States
Scientia Clinical Research
Randwick, New South Wales, Australia
Start Date
February 23, 2024
Primary Completion Date
December 1, 2026
Completion Date
December 1, 2026
Last Updated
March 13, 2025
NCT05720117
NCT06898450
NCT05719558
NCT05098132
NCT07477743
NCT07029399
Lead Sponsor
Synnovation Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions